β-hydroxybutyrate suppresses pathological changes of blood-induced arthropathy in rats
- PMID: 39614095
- PMCID: PMC11606947
- DOI: 10.1038/s41598-024-77074-6
β-hydroxybutyrate suppresses pathological changes of blood-induced arthropathy in rats
Abstract
Arthropathy is a common complication in haemophilia and decreases quality of life. It has been known that concentrations of β-hydroxybutyrate (BHB) in blood are increased by a ketogenic diet, and elevated levels of circulating BHB restricts the progression of inflammation-mediated joint pathological changes. We hypothesized that elevation of blood BHB concentrations could be effective for reducing the progression of bleeding-induced arthropathy by moderating the inflammatory responses of macrophages. In this study, we investigated whether BHB alleviates the arthropathy caused by repeated intra-articular blood injection in rats. To increase blood BHB levels, rats were fed with ketogenic diet. Repeated intra-articular blood injection induced significant joint swelling, whereas ketogenic diet intake significantly increased blood BHB concentrations and ameliorated the joint swelling. The periarticular tissue-fibrosis observed in the control diet intake group appeared to be significantly alleviated in the ketogenic diet intake group. In addition, the IL-1β, which is involved in the progression of arthropathy, levels in the supernatants of blood-exposed macrophages derived from THP-1 cell line were significantly suppressed by BHB supplementation. In summary, BHB moderated the pathological joint changes caused by intra-articular blood exposure.
© 2024. The Author(s).
Conflict of interest statement
Declarations. Competing interests: RK, AS, KT, NM, SH, TS, YN, and MS: members of Medical Biology of Thrombosis and Hemostasis established by Nara Medical University and Chugai Pharmaceutical Co., Ltd.RK, NM, SH, TS, YN, and YY: employees of Chugai Pharmaceutical Co., Ltd.RK, NM, SH, and YY: stock ownership of Chugai Pharmaceutical Co., Ltd.TS, YN, YY, and MS: Patents for inventions relating to products of Chugai Pharmaceutical Co., Ltd.AS: speaker’s bureau from CSL Behring.KT: grants or research support from Japan Blood Products Organization, The Mother and Child Health Foundation and Novo Nordisk Pharma.SM, MT, and SK: no competing interest.MS: representative of Medical Biology of Thrombosis and Hemostasis collaborative research laboratory.; research support from Chugai Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd. and CSL Behring.; honoraria or consultation fees from Chugai Pharmaceutical Co., Ltd.; speaker’s bureau from Chugai Pharmaceutical Co., Ltd., CSL Behring, Sanofi, Bayer, Novo Nordisk Pharma, Takeda Pharmaceutical Co., Ltd., Pfizer and Fujimoto Seiyaku Corp. RK, NM, SH, TS, YN, and YY: employees of Chugai Pharmaceutical Co., Ltd. RK, NM, SH, and YY: stock ownership of Chugai Pharmaceutical Co., Ltd. TS, YN, YY, and MS: Patents for inventions relating to products of Chugai Pharmaceutical Co., Ltd. AS: speaker’s bureau from CSL Behring. KT: grants or research support from Japan Blood Products Organization, The Mother and Child Health Foundation and Novo Nordisk Pharma. SM, MT, and SK: no competing interest. MS: representative of Medical Biology of Thrombosis and Hemostasis collaborative research laboratory.; research support from Chugai Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd. and CSL Behring.; honoraria or consultation fees from Chugai Pharmaceutical Co., Ltd.; speaker’s bureau from Chugai Pharmaceutical Co., Ltd., CSL Behring, Sanofi, Bayer, Novo Nordisk Pharma, Takeda Pharmaceutical Co., Ltd., Pfizer and Fujimoto Seiyaku Corp.
Figures






References
-
- Smolen, J. S., Aletaha, D. & McInnes, I. B. Rheumatoid arthritis. Lancet. 388, 2023–2038. 10.1016/s0140-6736(16)30173-8 (2016). - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources